Cell Gene Meeting on the Mesa - Precision BioSciences Transcript
Hello. My name is Cindy Atwell, and I'm VP of Business Development at Precision BioSciences. We are a clinical stage biotechnology company leveraging a next-generation genome editing platform for the development of therapeutics. We are a public company and I will be making forward-looking statements today. Please refer to the disclosures and risk factors in our SEC filings.
Precision BioSciences is dedicated to improving life through the application of our proprietary ARCUS genome editing platform. The focus of Precision BioSciences is to create therapeutics that address unmet medical needs.
Applying ARCUS, we are seeking to overcome cancer through the development of allogeneic CAR T therapies and the cure of rare diseases through in vivo gene correction. Our wholly owned subsidiary, Elo Life Systems also placed the ARCUS platform to improve human health through food. It has been an exciting year at Precision during which we have built a world-class team of 220 employees. We've established a GMP manufacturing facility and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
